Michael Callaghan, Phiet Bui | GenomeWeb

Michael Callaghan, Phiet Bui

Premium
Michael Callaghan resigned from Vermillion’s board on June 11, the company revealed in a document filed with the US Securities and Exchange Commission last week.
 
Callaghan left for personal reason and “not the result of any disagreement with the company on any matter relating to the company’s operations, policies, or practices,” Vermillion said in its document. Callaghan served on the audit and compensation committees of the board.
 

 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.